Secondary prevention medications post-CABG, such as aspirin and statins, are essential, while evidence for other agents like clopidogrel, beta-blockers, and ACE inhibitors remains less convincing.
What is the evidence for secondary prevention medications in post-CABG patients?
This review highlights that post-CABG patients have unique secondary prevention needs, with strong evidence for aspirin and statins but a need for more population-specific data for other agents.
Secondary prevention after coronary artery bypass graft (CABG) surgery is imperative in slowing the progression of atherosclerosis in both native and grafted vessels. Aspirin and statins remain the key medications for all patients without significant contraindications. The evidence for dual antiplatelet therapy with clopidogrel is less convincing, but there is hope for newer antiplatelet agents, such as ticagrelor. Meanwhile, β-blockers and angiotensin converting enzyme inhibitors might only offer benefits to specific sub-groups. Post-CABG patients appear to have different medication needs to the general cardiovascular patient and respond differently. In this review, we cover the drug regimens proposed by recent guidelines and the evidence behind their use. Assessing the evidence behind these recommendations, we find that there is an unmet need in some areas for robust population-specific evidence. We hope that future research will address this gap.
Dimitriadis et al. (Fri,) conducted a review in Post coronary artery bypass grafting (CABG). Secondary prevention medications was evaluated. Secondary prevention medications post-CABG, such as aspirin and statins, are essential, while evidence for other agents like clopidogrel, beta-blockers, and ACE inhibitors remains less convincing.